Navigation Links
Neurobiological Technologies Announces Filing of Certificate of Dissolution and Closing of Stock Transfer Books
Date:12/17/2009

EMERYVILLE, Calif., Dec. 17 /PRNewswire/ -- Neurobiological Technologies, Inc. (formerly NTII) ("NTI") announced today that it filed a Certificate of Dissolution with the Secretary of State of the State of Delaware on December 17, 2009. Certificates of Dissolution generally become effective upon filing. The Certificate of Dissolution provides for the dissolution of NTI under the Delaware General Corporation Law. In connection with the filing of its Certificate of Dissolution, NTI also closed its stock transfer books to coincide with the voluntary delisting of its securities from the Nasdaq Capital Market, effective prior to the opening of business on December 17, 2009.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions.

SOURCE Neurobiological Technologies, Inc.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share
2. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
3. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
4. Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
5. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
6. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
7. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
8. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
9. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
10. Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics
11. AVAX Technologies, Inc. Closes Bridge Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... 2017 operating results on Monday, August 7, 2017 after ... 5:00 p.m. ET. ... broadcast of the conference call by dialing 877-201-0168 or ... approximately 15 minutes prior to the call. A live ...
(Date:7/21/2017)... and RESEARCH TRIANGLE PARK, N.C. ... Corporation (NASDAQ: UTHR ) announced today that ... before the market opens on Thursday, July 27, 2017. ... host a teleconference on Thursday, July 27, 2017, at ... dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  A rebroadcast ...
(Date:7/21/2017)... , July 21, 2017 Did you know that ... in 2016? Or that combined spending on brand medicines, generics and ... spending, with brands accounting for just half of this (7 percent)? ... two thirds of the world,s venture capital investments in high-growth biopharmaceutical ... ...
Breaking Medicine Technology:
(Date:7/27/2017)... ... July 27, 2017 , ... ... 2012-2016, will keynote Day 2 of the HIMSS Healthcare Security Forum, the nation’s ... the Sheraton Boston Hotel, Sept. 11-13, 2017. , Daniel will deliver his keynote, ...
(Date:7/26/2017)... ... July 26, 2017 , ... Evergreen Healthcare Partners ... their continued efforts to provide innovative offerings to their healthcare partners. These solutions ... build dynamic, high-performing teams to address healthcare IT’s biggest challenges. , “Adding Talent ...
(Date:7/26/2017)... ... ... time to sign up for the new One-A-Month Essential Oil Club for fun and ... Naturals and author of numerous books on essential oils. , , ... , Two items are included in the December mailing. , A ...
(Date:7/26/2017)... Michigan (PRWEB) , ... July 26, 2017 , ... ... appointed Medical Director for the treatment program located in Royal Oak, Michigan. ... of investors who are focused on providing the highest standards in the field of ...
(Date:7/26/2017)... ... 2017 , ... The number of adults 65 years or older is expected ... asthma control in the population are not well described. In a study published in ... journal of the American Academy of Allergy, Asthma & Immunology (AAAAI), researchers identified factors ...
Breaking Medicine News(10 mins):